RenovoRx Appoints Mark Voll as Chief Financial Officer for Commercial Growth
ByAinvest
Friday, Feb 6, 2026 7:03 am ET1min read
RNXT--
RenovoRx has appointed Mark Voll as Chief Financial Officer, effective February 1, 2026. Voll brings over three decades of financial leadership experience, with a strong track record in guiding high-growth public companies through commercial buildout and strategic development. He joins RenovoRx to support the company's commercial growth of RenovoCath, a patented, FDA-cleared drug-delivery device. Voll's appointment strengthens RenovoRx's C-suite leadership and positions the company for future growth.
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue

Comments
No comments yet